文献速递瓣膜外科

超声吸引术治疗二尖瓣环钙化的早中期结局

Early and Intermediate Outcomes of Cavitron Ultrasonic Surgical Aspiration to Treat Mitral Annular Calcification.
PubMed 文献 · Eur J Cardiothorac Surg · 2026-01-01

该研究评估了67例严重二尖瓣环钙化(MAC)患者使用CUSA行二尖瓣手术的30天及中期结局。结果显示死亡率为6.0%,卒中3.0%,无房室沟破裂,中期全因死亡率在平均42.5个月随访时为9.0%,结论认为该技术短期并发症可接受且中期结果持久。

要点

  • CUSA可安全用于严重MAC的二尖瓣手术清创,短期死亡率和卒中率低。
  • 术后新发房颤发生率29.0%,需加强监测与管理。
  • 中期随访显示瓣周漏发生率低,生存结果可接受。

核心结论

  • 使用CUSA清创严重MAC与可接受的短期并发症和死亡率相关,且中期结果持久。

研究设计与样本

  • 单中心回顾性队列研究,纳入2021年3月至2024年12月连续67例严重MAC接受二尖瓣修复或置换术的患者,平均年龄72岁(SD 9),女性占65.7%(44/67)。

主要发现

  • 30天死亡率为6.0%(4/67),卒中为3.0%(2/67),新发术后房颤为29.0%(20/67)。
  • 无房室沟破裂发生。
  • 中位超声随访361天(IQR 112,671)时,中度瓣周漏发生率为3.0%(1/67)。
  • 平均随访42.5个月(95%CI 39.0,46.0)时,中期全因死亡率为9.0%。

关键数值与推荐

  • 手术方式包括:孤立二尖瓣置换41.8%(28/67)、孤立二尖瓣修复4.5%(3/67)、二尖瓣与主动脉瓣置换37.3%(25/67)、二尖瓣置换加冠脉搭桥6.0%(4/67)、二尖瓣与主动脉瓣置换加冠脉搭桥10.4%(7/67)。

临床怎么用

  • 对于严重MAC被认为手术风险过高者,CUSA辅助清创可使二尖瓣手术得以实施。
  • 术后需关注新发房颤及瓣周漏,定期超声随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Severe mitral annular calcification (MAC) carries an increased risk of perioperative complications in patients undergoing mitral valve surgery and may be considered a prohibitive surgical risk. Cavitron ultrasonic surgical aspiration (CUSA) has been reported as a method for controlled debridement of severe MAC during mitral valve surgery; however, experience in the literature is limited. METHODS: We assessed 30-day and intermediate-term outcomes in 67 consecutive patients (mean age: 72 [SD 9] years; female sex: 65.7% [44/67]) with severe MAC who underwent mitral valve repair or replacement for mitral stenosis and/or regurgitation using CUSA from March 2021 through December 2024. Operations included isolated mitral valve replacement (41.8% [28/67]), isolated mitral valve repair (4.5% [3/67]), mitral and aortic valve replacement (37.3% [25/67]), mitral valve replacement with coronary bypass (6.0% [4/67]), and mitral and aortic valve replacement with coronary bypass (10.4% [7/67]). Intermediate survival was estimated using the Kaplan-Meier method. RESULTS: Mortality rate was 6.0% (4/67), stroke was 3.0% (2/67), and new postoperative atrial fibrillation was 29.0% (20/67). There were no atrioventricular groove ruptures. At a median echocardiographic follow-up time of 361 days (interquartile range [IQR] 112, 671), moderate paravalvular leak occurred in 3.0% (1/67). Mid-term all-cause mortality was 9.0% at a mean follow-up time of 42.5 (95% CI, 39.0, 46.0) months. CONCLUSIONS: The use of CUSA to debride severe mitral annular calcification in patients undergoing mitral valve surgery is associated with acceptable short-term morbidity and mortality and durable intermediate-term results. This technique allows surgical intervention in patients who may otherwise be deemed prohibitive surgical risk.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Jin W, Hashim SW, Mckay RG, et al. Early and Intermediate Outcomes of Cavitron Ultrasonic Surgical Aspiration to Treat Mitral Annular Calcification. Eur J Cardiothorac Surg. 2026. PMID: 41494988. doi:10.1093/ejcts/ezag016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。